Catalent (NYSE:CTLT) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Catalent (NYSE:CTLT) in a note issued to investors on Wednesday. The brokerage set a “sell” rating on the stock.

A number of other research firms have also recently issued reports on CTLT. Royal Bank of Canada reiterated a “sector perform” rating and issued a $63.50 target price on shares of Catalent in a research note on Thursday, July 11th. Barclays lifted their price objective on Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research report on Friday, June 28th. Finally, William Blair restated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $58.08.

Catalent Stock Down 0.3 %

CTLT opened at $60.11 on Wednesday. The firm has a market cap of $10.88 billion, a price-to-earnings ratio of -9.85, a PEG ratio of 1.88 and a beta of 1.15. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.77 and a current ratio of 2.52. The firm’s 50-day simple moving average is $59.43 and its 200-day simple moving average is $57.19. Catalent has a twelve month low of $31.80 and a twelve month high of $61.20.

Insider Buying and Selling

In other news, SVP Scott Gunther sold 666 shares of the company’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $59.55, for a total transaction of $39,660.30. Following the transaction, the senior vice president now owns 39,635 shares of the company’s stock, valued at $2,360,264.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, SVP Scott Gunther sold 666 shares of Catalent stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $59.55, for a total transaction of $39,660.30. Following the completion of the sale, the senior vice president now owns 39,635 shares in the company, valued at approximately $2,360,264.25. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Alessandro Maselli sold 9,088 shares of the business’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $58.76, for a total transaction of $534,010.88. Following the sale, the chief executive officer now directly owns 177,521 shares of the company’s stock, valued at $10,431,133.96. The disclosure for this sale can be found here. Insiders sold 13,409 shares of company stock worth $782,923 in the last quarter. Insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Norges Bank acquired a new stake in shares of Catalent in the 4th quarter valued at approximately $116,021,000. Millennium Management LLC raised its holdings in Catalent by 129.2% in the second quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock worth $229,416,000 after purchasing an additional 2,299,784 shares during the period. Capital World Investors boosted its position in shares of Catalent by 6.1% during the fourth quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock worth $857,264,000 after purchasing an additional 1,098,474 shares in the last quarter. Magnetar Financial LLC acquired a new position in shares of Catalent in the 1st quarter valued at $56,429,000. Finally, Cadian Capital Management LP increased its position in shares of Catalent by 14.3% in the 4th quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock valued at $272,473,000 after buying an additional 759,600 shares in the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.